GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen ® KRAS RGQ ...
Researchers report that screening for KRAS and BRAF mutations can reduce the cost of anti-EGFR treatment for metastatic colorectal cancer but with a very small reduction in overall survival according ...
Roche is also running the Krascendo 2 trial of divarasib plus MSD's PD-1 inhibitor Keytruda (pembrolizumab) in first-line ...
A research team led by Minyoung Lee and Sunggyu Park of The Korea Institute of Materials Science (KIMS) Bio & Health ...
Daily Express US on MSN
New highly sensitive blood test detects traces of one of deadliest forms of cancer
The ultra-sensitive test can find hidden signs of pancreatic cancer by looking for a key KRAS genetic mutation missed by ...
Northwestern Medicine scientists have demonstrated that a highly sensitive blood test can detect traces of pancreatic cancer ...
Oncologist-Reported Reasons for Not Ordering Multimarker Tumor Panels: Results From a Nationally Representative Survey Supported in part by the United States Department of Veterans Affairs, Veterans ...
July 6, 2012 — The US Food and Drug Administration (FDA) has approved the therascreen® KRAS RGQ PCR Kit to be sold as a companion diagnostic test for cetuximab (Erbitux). In addition, the FDA has ...
Q: Should I be tested for the KRAS mutation before beginning colorectal cancer treatment? Recent research confirmed that the mutation status of the KRAS gene in colon cancer patients can determine if ...
Earlier blood-test detection could help identify pancreatic cancer patients who need more aggressive treatment, an expert ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results